Lupin gets FDA tentative approval for generic of contraceptive pill
Lupin Limited has secured tentative approval for its Abbreviated New Drug Application (ANDA) for Drospirenone Tablets, 4 mg from the US Food and Drug Administration (FDA).
According to the Indian pharma company, Drospirenone Tablets, 4 mg is the generic version of Slynd Tablets, 4 mg of Exeltis USA. Slynd Tablets (drospirenone) is an oral contraceptive.
See also Roivant Sciences launches Respivant Sciences to advance treatments for respiratory diseases
According to IQVIA MAT September 2022, the estimated annual sales for Drospirenone Tablets in the US is $141 million.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
Related Posts
CATEGORIES Pharma Industry News